SYDNEY, Australia — As escalating tensions in the Middle East, including the ongoing conflict involving Iran, threaten global supply chains for fuel, shipping, and food, Australians are increasingly concerned about potential disruptions to their access to essential medicines. The war has already led to delays in international shipping routes and restrictions on air transport, raising fears that these issues could ripple into the pharmaceutical sector. According to experts at The Conversation, while Australia's medicine supply system is equipped to weather short-term interruptions, prolonged instability could expose vulnerabilities in the nation's reliance on overseas production.
The conflict, which intensified in recent months with strikes and blockades in key maritime areas like the Strait of Hormuz, has disrupted trade flows critical to global commerce. Reports from international news outlets indicate that oil prices have surged, and shipping costs have risen by up to 30% in affected regions. For Australia, a country that imports more than 90% of its medicines, these developments are particularly worrisome. 'Australia produces some medicines and vaccines locally, but we are not self-sufficient,' notes an analysis published on theconversation.com. 'Even when medicines are made here, the raw ingredients are often imported.'
Primary sources of Australia's pharmaceutical imports include the United States, Europe, India, and China, with India and China playing pivotal roles in manufacturing raw ingredients known as active pharmaceutical ingredients (APIs). Disruptions in the Middle East could indirectly affect these chains, as even U.S.-based production depends on Asian suppliers. The fragility of this system was highlighted in the recent article, which describes medicine supply chains as 'less like a straight pipeline and more like a spider’s web.' If one strand—such as a factory in India or a shipping route through a conflict zone—breaks, the effects can weaken the entire network.
To mitigate such risks, Australia implemented stock-holding requirements in July 2023 for medicines subsidized under the Pharmaceutical Benefits Scheme (PBS). Manufacturers are now required to maintain at least four or six months' worth of stock on Australian soil, depending on the medicine. This buffer, distributed across wholesalers and pharmacies nationwide, including in regional areas, provides the Therapeutic Goods Administration (TGA) with time to respond to shortages. 'This creates a buffer. If a shortage begins, it gives the Therapeutic Goods Administration (TGA), our national medicines regulator, time to respond and reduce the impact,' the analysis explains.
The list of medicines subject to these requirements is under regular review, with another assessment scheduled for this month. This allows regulators to adapt priorities amid changing global conditions, such as the current Middle East crisis. However, not all medicines enjoy this protection. Those not listed on the PBS, including newer drugs and those available only via private prescription, face higher risks due to smaller stock buffers and fewer suppliers. These vulnerabilities could become acute if the Iran-related conflict persists, potentially delaying imports from affected regions.
Australia has been grappling with medicine shortages for several years, predating the latest geopolitical tensions. Common culprits include manufacturing issues, such as difficulties sourcing raw ingredients, and spikes in demand. For instance, ongoing shortages of attention-deficit hyperactivity disorder (ADHD) medications like lisdexamfetamine and methylphenidate stem from global demand surges and overseas production limits. Antibiotics and hormone replacement therapies have also been hit by manufacturing disruptions, while high demand for weight-loss drugs has strained supplies further.
Currently, 397 medicines are listed as in shortage by the TGA, a figure that has fluctuated but is slightly lower than peaks in recent years. The agency maintains a public database tracking current and anticipated shortages, offering guidance on management strategies. In the context of the Iran war, experts warn that war-related disruptions—such as blocked shipping routes, restricted air transport, or limited access to raw materials—could exacerbate these issues. 'War can disrupt this web in multiple ways,' the report states. 'Shipping routes may be blocked or delayed. Air transport can be restricted. Access to raw materials may be limited. Manufacturing can slow down.'
Even domestic logistics could be affected if fuel shortages from the conflict lead to higher transportation costs within Australia. The system's reliance on 'just-in-time' supply—where stocks are replenished frequently rather than hoarded—keeps prices low but leaves little margin for error during crises. This efficiency-driven model, while cost-effective, underscores Australia's dependence on stable global trade. Natural disasters, pandemics, and panic buying pose similar threats, and when combined with war, they heighten the likelihood of widespread shortages.
In the short to medium term, however, the existing buffers should suffice. 'Australia’s medicine supply chain is built to handle short disruptions. So you shouldn’t have problems accessing most common medicines in the short to medium term,' according to the expert commentary. But if disruptions extend beyond six months, risks escalate, particularly for medicines produced by few manufacturers or reliant on single raw ingredients. The analysis emphasizes that the system 'isn’t designed for prolonged global instability.'
The TGA has tools to address emerging shortages. Under Section 19A approvals, the agency can permit temporary importation of medicines approved in other countries, sometimes even subsidizing them under the PBS. Pharmacists may also dispense alternative formulations of the same medicine without a new prescription, maintaining patient access. These measures have proven effective in past disruptions, such as during the COVID-19 pandemic when supply chains faced immense pressure.
Addressing the root causes would require boosting local manufacturing, a move that could enhance resilience but demands significant time and investment. 'Increasing local manufacturing would improve resilience but it would take time and significant investment,' the report acknowledges. Australia has explored this option, with government initiatives to onshore some production, but progress has been slow due to high costs compared to overseas manufacturing.
For everyday Australians, the advice is straightforward: avoid panic buying or stockpiling, which could worsen shortages. Patients should keep prescriptions current and plan ahead to prevent running out. 'If you’re concerned, speak to your pharmacist and doctor. If your medicine is in short supply, there may be alternatives or ways to source your medicine from another location,' experts recommend. Health professionals and policymakers have multiple response avenues to ensure continuity of care.
The broader implications of the Iran conflict extend beyond medicines to food and energy security, painting a picture of interconnected global vulnerabilities. As the war shows no immediate signs of resolution, with recent reports of escalated military actions, Australian officials are monitoring the situation closely. The TGA's upcoming review of stock-holding lists could incorporate these risks, potentially expanding protections.
In the end, while Australia's safeguards have managed disruptions before, the current geopolitical landscape tests the limits of this framework. With 90% of medicines imported and supply chains spanning conflict-prone areas, the nation remains alert. As one expert puts it, 'Australia’s medicine supply chain is designed to manage disruption and it has done so before. While global pressures are increasing, there are safeguards in place and multiple ways health professionals and policy makers can respond to help you if shortages occur.'
This story underscores the delicate balance of modern supply chains in an era of uncertainty. For now, most Australians can access their medications without issue, but vigilance is key as the Middle East crisis unfolds.